{"url_path":"/sec/aim/8-k/2026-06-04/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-027210-index.html","accession_number":"0001493152-26-027210","cik":"0000946644","ticker":"AIM","issuer_name":"AIM ImmunoTech Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-027210-index.html","primary_entity_key":"0000946644","primary_entity_name":"AIM ImmunoTech Inc."},"word_count":317,"has_tables":true,"body_markdown":"**Item\n7.01**\n**Regulation\nFD Disclosure.**\n\n \n\nOn\nJune 4, 2026, AIM ImmunoTech Inc. (the “Company”) released an on-demand video presentation detailing previously published\npre-clinical findings relating to the potential role of its lead drug candidate Ampligen® (rintatolimod) as a prophylactic and/or\nearly-onset antiviral treatment for Ebola virus disease (“EVD”). The Virtual Investor “What This Means” segment\nis available for viewing at https://virtualinvestorco.com/aim. A copy of the press release relating to the video presentation is furnished\nas Exhibit 99.1 hereto and incorporated herein by reference. Additionally, an Investor Presentation slide deck of information related\nto the Company’s research into EVD is available for viewing on the Company’s website at https://aimimmuno.com/presentations,\nis furnished as Exhibit 99.2 hereto, and is incorporated herein by reference.\n\n \n\nThe\ninformation furnished under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of\nSection 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference\nin any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.\n\n \n\n**Cautionary\nNote Regarding Forward-Looking Statements**\n\n \n\nThis\nCurrent Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended\n(the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),\nincluding statements regarding the potential role of Ampligen® as a prophylactic or early-onset antiviral treatment for EVD. These\nstatements are subject to risks and uncertainties that could cause actual results to differ materially, including but not limited to\nrisks related to clinical development, regulatory approval, and other factors described in the Company’s filings with the Securities\nand Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company\nundertakes no obligation to update any forward-looking statements."}